

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
LUX-VALVE PLUS APPROVED FOR
HONG KONG-MACAO MEDICINE AND EQUIPMENT CONNECT

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated data in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, LuX-Valve Plus transjugular tricuspid valve replacement system, the product of Jenscare Scientific (Netherlands) B.V., a subsidiary of the Group, has been officially approved to be included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, enabling commercial clinical application in designated medical institutions in the mainland of the Greater Bay Area.

“Hong Kong-Macao Medicine and Equipment Connect” is a medical innovation policy implemented in the Guangdong-Hong Kong-Macao Greater Bay Area of China, which allows medicines or medical devices that have been purchased and used by public hospitals in Hong Kong and Macao and are urgently needed for clinical purpose in the Mainland to be used in designated medical institutions in the mainland of the Guangdong-Hong Kong-Macao Greater Bay Area after approval, aiming to meet patients’ urgent needs for advanced medical technology, to offer patients with more diversified treatment options, and to provide an efficient access pathway for innovative medical devices.

LuX-Valve Plus has successfully obtained the approval of “Hong Kong-Macao Medicine and Equipment Connect” for commercial clinical application in the mainland of the Guangdong-Hong Kong-Macao Greater Bay Area by leveraging its extensive successful clinical application experience, outstanding clinical performance and unique and advanced product design in major countries and regions worldwide, including Asia-Pacific, North America, Europe, South America, and Middle East. Through this access pathway, LuX-Valve Plus is expected to initially meet the urgent and substantial treatment needs of patients suffering from tricuspid regurgitation in the region.

LuX-Valve Plus is an independently developed transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Tricuspid regurgitation presents significant unmet clinical needs, particularly in cases involving severely dilated tricuspid annular and complex anatomical structures, where safe and effective treatment options have long been scarce. LuX-Valve Plus features a globally innovative valve design with ventricular-septum anchoring and a self-adaptive anti-leak ring. Delivered via the transjugular approach and available in seven sizes (40mm-70mm), it is suitable for patients with tricuspid regurgitation who presents various anatomical challenges and barely has other treatment options, demonstrating outstanding clinical performance. The product has been successfully implanted worldwide in numerous cases, with follow-up results showing good safety profiles and outstanding efficacy. Its technological advancement and clinical value have gained widespread recognition in the international market.

We will take full advantage of the policy opportunity of the “Hong Kong-Macao Medicine and Equipment Connect”, actively promote commercial implantation of LuX-Valve Plus in the Greater Bay Area, accelerate market penetration, and proactively address the unmet clinical needs of a large number of patients. Meanwhile, this will further accumulate essential experience for the subsequent comprehensive expansion of LuX-Valve Plus in domestic and overseas markets, driving the Group to achieve long-term sustainable revenue growth.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei

Executive Director and Chief Executive Officer

Hong Kong, October 9, 2025

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.